47. Zhang Y, et al. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease. Eur J Pharm Biopharm 2020, 155, 128-138.

46. Book chapter. Alelwani, W., Alharbi, R. A., Wan, D., Vllasaliu, D., Falcone, F. & Stolnik, S. Use of Engineered Nanoparticles (ENPs) for the Study of High-Affinity IgE FcεRI Receptor Engagement and Rat Basophilic Leukemia (RBL) Cell Degranulation: Basophils and Mast Cells. Methods in Molecular Biology: Basophils and Mast Cells. Humana Press, 2020, Vol. 2163 


45Mašková E, et al. Hypromellose – A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. Journal of Controlled Release.

44. Carobolante G, et al. Cow Milk and Intestinal Epithelial Cell-derived Extracellular Vesicles as Systems for Enhancing Oral Drug Delivery. Pharmaceutics.

43. Mantaj J and Vllasaliu D. Recent advances in the oral delivery of biologics. The Pharmaceutical Journal, January 2020, 304, 7933. doi:10.1211/PJ.2020.20207374



42. Muraleetharan V, et al. Nanoparticle modification in biological media: implications for oral nanomedicines. RSC Advances 2019, 9, 40487-40497. 

41. Perinelli D R, et al. PEGylation affects the self-assembling behavior of amphiphilic octapeptides. International Journal of Pharmaceutics 2019, 571, 118752.

40. Yong J. et al. Delivery of nanoparticles across the intestinal epithelium via the transferrin transport pathway. Pharmaceutics 2019, 11(7): E298.


39. Perinelli D R, et al. Quaternary Ammonium Leucine-Based Surfactants: The Effect of a Benzyl Group on Physicochemical Properties and Antimicrobial Activity. Pharmaceutics 2019, 11(6):287.

38. Pazhanimala SK. Engineering Biomimetic Gelatin Based Nanostructures as Synthetic Substrates for Cell Culture. Appl Sci 2019, 9, 1583.

37. Perinelli D R, et al. Quaternary ammonium surfactants derived from leucine and methionine: novel challenging surface active molecules with antimicrobial activity. Journal of Molecular Liquids. Accepted 15/3/19. 10.1016/j.molliq.2019.03.083

36. Aprodu A, et al. Evaluation of a Methylcellulose and Hyaluronic Acid Hydrogel as a Vehicle for Rectal Delivery of Biologics. Pharmaceutics 2019, 11(3), 127. doi:10.3390/pharmaceutics11030127


35. Pazhanimala S, et al. Electrospun Nanometer to Micrometer Scale Biomimetic Synthetic Membrane Scaffolds in Drug Delivery and Tissue Engineering: A Review. Appl Sci 2019, 9(5):910.


34. Turcanu, MV, et al. Ultrasound and Microbubbles Promote the Retention of Fluorescent Compounds in the Small Intestine. 2018 IEEE International Ultrasonics Symposium, IUS 2018. IEEE Computer Society, Vol. 2018-October.

33. Mantaj J, et al. The Role of Basement Membrane in Intestinal Barrier to Absorption of Macromolecules and Nanoparticles. Mol Pharm 2018, 15(12):5802-5808 

32. Zhai J, et al. Ascorbyl Palmitate Hydrogel for Local, Intestinal Delivery of Macromolecules. Pharmaceutics 2018, 10(4):188.

31. Vllasaliu D, et al. Recent advances in oral delivery of biologics: nanomedicine and physical modes of delivery. Expert Opin Drug Deliv. 2018, 15:759-770.

30. Hashem L, et al. Intestinal uptake and transport of albumin nanoparticles: potential for oral delivery. Nanomedicine. 2018, 13:11.

29. Cole H, et al. Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery. Carbohydr Polym. 2018, 190:248-254.

28. Capel V, Vllasaliu D, et al. Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA. Drug Deliv. 2018, 25:644-653.

27. Perinelli D, et al. Lactose oleate as new biocompatible surfactant for pharmaceutical applications. Eur J Pharm Biopharm. 2018, 124:55-62.   


26. Perinelli, D, et al. Rhamnolipids as epithelial permeability enhancers for macromolecular therapeutics. Eur J Pharm Biopharm 2017, 119:419-425.

25. Bird J, et al. Neurotensin receptor 1 facilitates intracellular and transepithelial delivery of macromolecules. Eur J Pharm Biopharm 2017, 119:300-309


24. Perinelli D, et al. Correlation among chemical structure, surface properties and cytotoxicity of N-acyl alanine and serine surfactants. Eur J Pharm Biopharm 2016, 109:93-102.

23. Lucarini S, et al. Unsaturated fatty acids lactose esters: cytotoxicity, permeability enhancement and antimicrobial activity. Eur J Pharm Biopharm 2016, 107:88-96.

22. Capel V, et al. Insight into the relationship between the cell culture model, cell trafficking and siRNA silencing efficiency. Biochem Biophys Res Commun 2016, 477 (2):260-265.


21. Byrne G, Vllasaliu D, et al. Live imaging of cellular internalization of single colloidal particle by combined label-free and fluorescence Total Internal Reflection Microscopy. Mol Pharm 2015, 12, (11):3862-70.

20. Daci A, et al. Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar albanian epileptic patients. PloS one 2015, 10, (11):e0142408.

19. Shubber S, Vllasaliu D, et al. Mechanism of mucosal permeability enhancement of CriticalSorb. (Solutol. HS15) Investigated In Vitro in Cell Cultures. Pharm Res 2015, 32, (2):516-27.


18. Bannunah A, Vllasaliu D, et al. Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol Pharm 2014, 11, (12):4363-73.

17. Vllasaliu D and Singh I. Particle characterisation in drug delivery. European Pharmaceutical Review 09/2014.

16. Garnett M, Vllasaliu D, et al. Drug delivery - epithelial cell models for drug transport and toxicology studies. Biochemist 06/2014; 36(3).

15. Vllasaliu D, et al. Basement membrane influences intestinal epithelial cell growth and presents a barrier to the movement of macromolecules. Exp Cell Res 2014, 323, (1):218-31.

14. Vllasaliu D, et al. PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin Drug Deliv 2014, 11, (1):139-54.



13. Fowler R, Vllasaliu D, et al. Uptake and transport of B12-conjugated nanoparticles in airway epithelium. J Control Release 2013, 172:374-381.

12. Vllasaliu D, et al. Folic acid conjugated chitosan nanoparticles for tumor targeting of therapeutic and imaging agents. Pharm Nanotechnol 2013, 1:184-203.

11. Fowler R, Vllasaliu D, et al. Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small 2013, 9:3282-94.

10. Vllasaliu D, et al. Epithelial toxicity of alkylglycoside surfactants. J Pharm Sci 2013, 102:114-25.


9. Casettari L, Vllasaliu D, et al. Biomedical applications of amino acid-modified chitosans: A review. Biomaterials 2012, 33, (30):7565-7583.

8. Vllasaliu D, et al. Absorption-promoting effects of chitosan in airway and intestinal cell lines: a comparative study. Int J Pharm 2012, 430, (1-2):151-160.

7. Moradi E, Vllasaliu D, et al. Ligand density and clustering effects on endocytosis of folate modified nanoparticles. RSC Advances 2012, 2:3025-3033.

6. Vllasaliu D, et al. Evaluation of calcium depletion as a strategy for enhancement of mucosal absorption of macromolecules. Biochem Biophys Res Commun 2012, 418, (1):128-133.

5. Vllasaliu D, et al. Fc-mediated transport of nanoparticles across airway epithelial cell layers. J Control Release 2012, 158, (3):479-486.

4Casettari L, Vllasaliu D, et al. PEGylated chitosan derivatives: Synthesis, characterizations and pharmaceutical applications. Progress in Polymer Science 2012, 37, (5): 659-685


3. Vllasaliu D, et al. Barrier characteristics of epithelial cultures modelling the airway and intestinal mucosa: a comparison. Biochem Biophys Res Commun 2011, 415, (4):579-585.

2. Casettari L, Vllasaliu D, et al. Effect of PEGylation on the Toxicity and Permeability Enhancement of Chitosan. Biomacromolecules 2011, 11:2854-2865.


1. Vllasaliu D, et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J Pharm 2010, 400, (1-2):183-193.